Novel Approaches in Limited Stage and Extensive Stage Small Cell Lung Cancer
The role of multidisciplinary care for small cell lung cancer has never been more important. Novel insights into subclassification of small cell lung cancer may unlock novel therapies that may be effective for each subtype. Emerging use of stereotactic radiosurgery for brain metastases in small cell lung cancer may reduce toxicities while maintaining efficacy. Finally, novel combinations of radiation therapy with immunotherapy and other novel systemic agents in limited stage small cell lung cancer may improve outcomes for these patients.
There are many ongoing advances in the treatment of limited stage and extensive stage small cell lung cancer. Failure to stay informed leads to potentially delivering suboptimal quality of care by practicing physicians.
It is imperative that practicing clinician stay current in the developing subclassification for small cell lung cancer, novel systemic treatment options in second and third line therapies, novel radiation delivery approaches and combinations with systemic agents, as well as current approaches to address brain metastases in small cell lung cancer.
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.
Upon completion of this activity, participants should be able to do the following:
- Understand the emerging subclassifications for small cell lung cancer that may lead to different effective therapies.
- Determine which small cell lung cancer patients with brain metastases are appropriately treated with stereotactic radiosurgery.
- Understand current trials combining radiation therapy and systemic therapies such as immunotherapies for both limited stage and extensive stage small cell lung cancer patients.
- Percy Lee, MD
- Jyoti Malhotra, MD, MPH
- Kristin Higgins, MD
- Vinai Gondi, MD
A list of all meeting faculty and Individual presenter disclosures are linked to their names in the Schedule of Events.
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee website page.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.